Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

(2011) D. T. Felson et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast Cancer Resistance Protein) on the Oral Pharmacokinetics of Methotrexate and Its Main Metabolite 7-Hydroxymethotrexate

(2011) M. L. H. Vlaming et al.   DRUG METABOLISM AND DISPOSITION

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype

(2011) Silvia Selinski et al.   Pharmacogenetics and Genomics

The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine

(2008) Jun Guan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

(2008) Y Yamasaki et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Therapeutic Effects of Alendronate on Bone Erosion and Atrophy in a Patient with Rheumatoid Arthritis and Hepatitis C Virus Infection

(2008) MAKOTO SOEJIMA et al.   JOURNAL OF RHEUMATOLOGY

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

(2008) Bradley L. Urquhart et al.   Pharmacogenetics and Genomics